Company News »

Ignyta to Present at Livingston Securities Life Science Stakeholders Summit

Business Wire
Share on StockTwits
Published on

Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Jacob Chacko, M.D., Chief Financial Officer, will make a presentation at the Livingston Securities Life Science Stakeholders Summit on October 1, 2014 at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in Philadelphia, PA.

A webcast of the presentation will be available during the event at https://www1.gotomeeting.com/join/656225217. A webcast of the presentation will also be available during the event in the Investors section of the company’s website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. The company’s goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. Ignyta’s present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets multiple solid tumor indications, the development of its newly-licensed RXDX-103 and RXDX-104 kinase inhibitors, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. For more information, please visit: www.ignyta.com.

Share on StockTwits